Mike Pence on Leadership and the Future of the Republican Party
Former US Vice President Mike Pence looks back on the events of January 6 2021, his final days in office with President Trump and his…
Thought Leader: Mike Pence
Can an inflation cap on drugs be inflationary?
By Scott Gottlieb (original source AEI)
Members of the Senate Finance Committee have fashioned a well-meaning effort to modernize the Medicare drug benefit. Among its key features, the bill would help protect seniors from high out-of-pocket costs by limiting beneficiary cost sharing to $3,100 annually. It then seeks to offset some of these new subsidies by capping the increases that drug makers can take on the list price of their medicines.
In this way, the bill reflects a wider policy struggle underway in our debate over drug pricing. On the one hand, drug makers want to broaden coverage for medicines in programs like Medicare and Obamacare as a way to better insulate consumers from drug costs. On the other hand, policy makers don’t want to expand government funding for drugs without imposing more control over how these products are priced.
Click to read more
Relevant and recent posts
Marc Short on U.S. Investment in Critical Minerals
Why do critical minerals matter now? Marc Short explains how U.S. investment in critical minerals fits into a broader strategy around economic security, manufacturing, and…
Thought Leader: Marc Short
Marc Short on AI Policy and the Government’s Role in Chip Technology Investment
On CNBC, Marc Short breaks down the role of AI policy and how government investment is shaping the future of chip technology. A former Chief…
Thought Leader: Marc Short
More with this speaker
Dr. Scott Gottlieb on Finding Cures for Rare Diseases
Thought Leader: Scott Gottlieb
Dr. Scott Gottlieb: What’s Next for Childhood Vaccines
Thought Leader: Scott Gottlieb
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb